Targeting Glutaminase Isoforms GLS and GLS2 in Luminal Breast Cancer
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27062780 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Brendah K Masisi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nottingham Breast Cancer Research Centre, Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham Biodiscovery…. Hauptthemen laut MEDLINE: Glutaminase, Breast Neoplasms, Benzeneacetamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nottingham Breast Cancer Research Centre, University of Botswana.
Abstract (Originalsprache)
Upregulation of glutaminase enzymatic activity promotes tumour cell proliferation. Its overexpression correlates with poor disease outcome in patients, including those with breast cancer. A selective glutaminase inhibitor, CB-839, which targets cancer cells by blocking glutamine conversion to glutamate, has shown promising preclinical results as a therapeutic target in triple-negative breast cancer treatment. The current study aimed to determine the importance of glutaminase in Oestrogen Receptor positive/luminal breast cancer to potentially identify therapeutic targets to treat this subtype. In vitro studies using luminal breast cancer cells were performed to investigate the effects of siRNA knockdown of glutaminase genes (GLS and GLS2) and inhibition using CB-839 on functional assays. Silencing GLS in luminal breast cancer cells significantly reduced cell proliferation whilst inducing apoptosis. A similar impact on cell proliferation was observed when silencing GLS2 in luminal B cells, but there was no observed effect on cell apoptosis and cell cycle. There was little effect of GLS inhibition using CB-839 in luminal breast cancer. This study demonstrates that glutaminase is necessary for luminal breast cancer growth and survival. Co-targeting GLS and GLS2 might be a novel approach for the treatment of this subclass. Further functional studies to evaluate the underlying molecular mechanisms of this process are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nottingham Breast Cancer Research Centre, Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK.
- School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Plot 4775 Notwane and Mobuto Road, Gaborone P/Bag UB 0022, Botswana.
- Department of Cellular Pathology, Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK.
ORCID-Profile: Andrew R Green
Förderung
- Nottingham Breast Cancer Research Centre
- University of Botswana
Zitieren
APA
Masisi, B. K., El Ansari, R., Fakroun, A., Erkan, B., Rakha, E. A., & Green, A. R. (2026). Targeting Glutaminase Isoforms GLS and GLS2 in Luminal Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27062780
Vancouver
Masisi BK, El Ansari R, Fakroun A, Erkan B, Rakha EA, Green AR. Targeting Glutaminase Isoforms GLS and GLS2 in Luminal Breast Cancer. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27062780
BibTeX
@article{Masisi2026,
author = {Masisi, Brendah K and El Ansari, Rokaya and Fakroun, Ali and Erkan, Büsra and Rakha, Emad A and Green, Andrew R},
title = {Targeting Glutaminase Isoforms GLS and GLS2 in Luminal Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27062780}
}
EUVIMED